We serve Chemical Name:4-(Aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole CAS:91366-65-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(Aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole
CAS.NO:91366-65-3
Synonyms:7-Fluoro-2,1,3-benzoxadiazole-4-sulfonamide;2,1,3-Benzoxadiazole-4-sulfonamide, 7-fluoro-;MFCD00036687
Molecular Formula:C6H4FN3O3S
Molecular Weight:217.178
HS Code:2935009090
Physical and Chemical Properties:
Melting point:145-146ºC
Boiling point:408.8±55.0 °C at 760 mmHg
Density:1.7±0.1 g/cm3
Index of Refraction:1.632
PSA:107.46000
Exact Mass:216.995743
LogP:0.11
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 7-Fluoro-2,1,3-benzoxadiazole-4-sulfonamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00036687 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,1,3-Benzoxadiazole-4-sulfonamide, 7-fluoro- Use and application,7-Fluoro-2,1,3-benzoxadiazole-4-sulfonamide technical grade,usp/ep/jp grade.
Related News: The company reported that it was cooperating with the Justice Department probe and that an outside law firm was also “investigating these allegations thoroughly.” 4-(Aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole manufacturer The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 4-(Aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole supplier The company reported that it was cooperating with the Justice Department probe and that an outside law firm was also “investigating these allegations thoroughly.” 4-(Aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole vendor The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 4-(Aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole factory The company reported that it was cooperating with the Justice Department probe and that an outside law firm was also “investigating these allegations thoroughly.”
